Merck, the last Big Pharma standing in CETP inhibition, is pressing forward with a huge cardiovascular trial after getting the green light from its independent advisers, stepping over the scattered failures of similar projects in hopes of hitting upon a blockbuster.
Three years ago, Eli Lilly heart specialist Jeffrey Riesmeyer scoffed at the notion that the failure of CETP inhibitors at Roche and Pfizer was a bad sign for their big Phase III program for evacetrapib. Evacetrapib wound up proving that Lilly was dead wrong about its theory.
Merck's experimental anacetrapib is one of those massively expensive lottery programs that can spur dreams of huge revenue streams.
Merck is in a world of hurt. The pharma giant managed to spook several analysts with the news that its osteoporosis drug odanacatib would be held back from regulators until more data could be obtained in a trial extension, raising fears that the badly needed drug may be about to jump the tracks.
Even as failures in the field pile up, Merck CEO Kenneth Frazier is pushing ahead with a massive development program for a drug to boost HDL or "good" cholesterol.
In the wrap-up of the European Society of Cardiology meeting in Munich, Reuters ' Ben Hirschler assessed the field in search of the next potential Lipitors in the pipeline--megablockbusters that will cost hundreds of millions of dollars to test in huge clinical trials--and came up with three big fields. Each of them has big caveats to consider.
Merck has revealed updates for key meds in the U.S. drug giant's pipeline of cardiovascular drugs. And the plans call for the company to ask regulators for approvals of two cardio drugs--vorapaxar and Tredaptive--next year as the Whitehouse Station, NJ-based pharma works to beef up its lineup of commercial products.
With Wall Street demanding increased pipeline productivity from drug giants, Merck ($MRK) showed analysts and others exactly what investors are getting from one of the largest research budgets in the...
Merck ($MRK) scored a coup at the American Heart Association meeting as it unveiled an impressive set of pivotal data on its closely-watched cholesterol drug anacetrapib. Widely billed as a potential
Four years after Pfizer pulled the plug on its $1 billion development program for the failed cholesterol drug torcetrapib, Merck is on the verge of announcing the first late-stage data on its own